Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Methotrexate Safety in Psoriasis with Metabolic Syndrome
NCT04469829Phase 4Unknown
- Sponsor
- Università degli Studi di Verona
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in psoriasis, sponsored by Università degli Studi di Verona. Status: unknown.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04469829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469829.